InvestSMART

ReNerve Limited (ASX:RNV)

ALERT: Price-sensitive ASX Announcement for RNV
Current share price for RNV : $0.080 0.001 (1.27%)+
Announcement
Release
9 Jul 2026 9:05AM
Price at Release
$0.079
Full Release
download
Summary
ReNerve Limited has secured a convertible note funding facility with RiverFort Global Opportunities PCC Ltd for up to A$5 million. This facility allows ReNerve flexible access to capital over a three-year period to support its commercialization strategy, working capital, and corporate needs. The initial drawdown will provide approximately A$1.6 million in gross proceeds. The funding will aid ReNerve in expanding its product portfolio, enhancing US sales and distribution, and pursuing market development initiatives. The facility's staged structure enables access to capital as needed, while managing dilution and cash flow. Convertible securities issued under the facility will be subject to a maximum dilution of 16,054,394 shares for the initial drawdown. ReNerve is advancing its nerve repair solutions, with a product portfolio including the FDA-cleared NervAlign® Nerve Cuff and other innovative medical devices.
Key Points
  • ReNerve secures up to A$5 million funding facility with RiverFort.
  • Facility provides flexible, staged access to capital over three years.
  • Initial drawdown of approximately A$1.6 million in gross proceeds.
  • Funding supports commercialization, product expansion, and market initiatives.
  • Convertible securities issued with a maximum dilution for initial drawdown.
  • ReNerve advancing nerve repair solutions with innovative medical devices.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.